Phosphodiesterase 4 inhibitors have only marginal benefits for people with COPD
Wednesday, May 11, 2011 - 03:30
in Health & Medicine
Giving patients with chronic obstructive pulmonary disease (COPD) newly available oral phosphodiesterase 4 (PDE4) inhibitors, roflumilast or cilomilast, improves lung function and reduces the likelihood of a flareup, but does not increase general quality of life. These are the findings of a new systematic review by Cochrane researchers.